D
David Wojciechowski
Researcher at Harvard University
Publications - 53
Citations - 627
David Wojciechowski is an academic researcher from Harvard University. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 14, co-authored 48 publications receiving 507 citations. Previous affiliations of David Wojciechowski include United States Department of Veterans Affairs & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients.
Deepali Kumar,Peter Chin-Hong,Liise K. Kayler,David Wojciechowski,Ajit P. Limaye,A. Osama Gaber,Simon Ball,Aneesh K. Mehta,Matthew Cooper,Ted Blanchard,James MacDougall,Camille N. Kotton +11 more
TL;DR: In this large, multicenter trial of kidney transplant recipients, an assessment of CMV‐specific immunity using a novel ELISPOT assay is able to predict protection from CMV infection.
Journal ArticleDOI
Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year.
David Wojciechowski,Ranjan Chanda,Sindhu Chandran,Brian Lee,Allison B. Webber,Melanie Macaraig,Stephen J. Tomlanovich,Flavio Vincenti +7 more
TL;DR: Thirty-day ciprofloxacin prophylaxis in kidney transplant recipients is associated with a lower rate of BKV infection at 3 months but not at 12 months, and the long-term effectiveness and optimal duration of fluoroquinolones against BKv infection remain unknown.
Journal ArticleDOI
Cultural competency of a mobile, customized patient education tool for improving potential kidney transplant recipients’ knowledge and decision‐making
David A. Axelrod,Crystal S. Kynard-Amerson,David Wojciechowski,Marie Jacobs,Krista L. Lentine,Mark A. Schnitzler,John D. Peipert,Amy D. Waterman +7 more
TL;DR: This pilot project confirmed the benefit and cultural acceptability of this educational tool, and further refinement will explore how to better communicate the risks and benefits of nonstandard donors.
Journal ArticleDOI
Belatacept in kidney transplantation.
TL;DR: Belatacept is the first new agent available in kidney transplant that may achieve the goal of improved long-term renal function and one safety issue that must be considered is the potential for increased risk of posttransplant lymphoproliferative disease, especially in Epstein–Barr virus-seronegative recipients or patients treated with lymphocyte-depleting agents.
Journal ArticleDOI
Organs from deceased donors with false-positive HIV screening tests: An unexpected benefit of the HOPE act.
Christine M. Durand,Samantha E. Halpern,Mary G. Bowring,Gilad A. Bismut,Oyinkansola T. Kusemiju,Brianna Doby,Reinaldo E Fernandez,Charles S. Kirby,Darin Ostrander,Peter G. Stock,Shikha Mehta,Nicole A. Turgeon,David Wojciechowski,Shirish Huprikar,Sander Florman,Shane Ottmann,Niraj M. Desai,Andrew M. Cameron,Allan B. Massie,Aaron A.R. Tobian,Aaron A.R. Tobian,Andrew D. Redd,Andrew D. Redd,Dorry L. Segev,Dorry L. Segev +24 more
TL;DR: Given the false‐positive rates of approved assays used to screen > 20 000 deceased donors annually, it is estimated 50‐100 HIVfalse‐positive donors per year are likely to be found.